PharmAbcine Signs Business Agreement with FutureChem to Promote Entry into Radiopharmaceutical Market

[Asia Economy Reporter Hyungsoo Park] PharmAbcine announced that it has signed a Memorandum of Understanding (MOU) to conduct joint research with FutureChem, a specialized company in radioligands, aiming to develop new radiopharmaceuticals.

The signing ceremony held on the 23rd at PharmAbcine's headquarters was attended by PharmAbcine CEO Eugene San Yoo, Executive Director Hyunseon Park, FutureChem CEO Daeyoon Ji, and Managing Director Heeseop Gil, among others.

PharmAbcine aims to develop first-in-class innovative drugs by utilizing its antibodies and FutureChem's radiopharmaceutical manufacturing technology. They plan to derive candidate substances for radiotherapeutics and conduct efficacy evaluations.

PharmAbcine is a specialized antibody drug development company that owns the fully human antibody library 'HuPhage.' It actively engages in open innovation with drug development companies across various fields.

FutureChem develops and sells radiopharmaceuticals for diagnosing Parkinson's disease, Alzheimer's disease, cancer, and more. Currently, it is conducting clinical trials for prostate cancer diagnostics and therapeutics both domestically and internationally.

Radiopharmaceuticals refer to radiobiochemical substances that combine radioactive isotopes (isotopes possessing radioactivity) with peptides targeting specific proteins. Radiopharmaceuticals are drugs manufactured by labeling diagnostic or therapeutic radioactive isotopes accordingly.

Therapeutic radioactive isotopes target specific proteins expressed in cancer, allowing the therapeutic agent to enter only cancer cells, enabling targeted therapy. Radiopharmaceuticals have the advantage of enabling simultaneous diagnosis and treatment, allowing effective evaluation of the progress or outcomes of anticancer therapy at once.

This content was produced with the assistance of AI translation services.